Obesity Reduces Remimazolam ED50 by 26% in Pediatric Procedural Sedation, Study Finds
Key Insights
A prospective trial found the ED50 of remimazolam for procedural sedation was 0.17 mg/kg in obese children versus 0.23 mg/kg in normal-weight peers, a 26% reduction.
The study used an up-and-down sequential allocation design in 60 pediatric patients aged 6–18 undergoing circumcision with remifentanil co-administration.
Obese pediatric patients experienced a higher incidence of hypoxemia (8 of 12 cases), suggesting greater respiratory vulnerability despite no statistically significant difference between groups.
A new prospective clinical study has demonstrated that obesity (search) significantly reduces the median effective dose (ED50) of remimazolam required for procedural sedation in pediatric patients. Published in Drug Design, Development and Therapy, the trial found that obese children aged 6–18 years required approximately 26% less remimazolam per kilogram of body weight compared to their normal-weight counterparts when undergoing dorsal penile nerve block for circumcision.
The ED50 of remimazolam was 0.17 mg/kg (95% CI: 0.14–0.19 mg/kg) in the obese group versus 0.23 mg/kg (95% CI: 0.19–0.24 mg/kg) in the normal-weight group, a difference that reached statistical significance (P < 0.001). Using probit regression, the ED50 values were estimated at 0.16 mg/kg (95% CI, 0.15–0.17 mg/kg) and 0.22 mg/kg (95% CI, 0.21–0.24 mg/kg), respectively, with a relative median potency of 0.74 (95% CI: 0.41–0.91) for obese patients.
Study Design and Methodology
Conducted at the Affiliated Women's and Children's Hospital of Ningbo University (search), the trial enrolled 60 pediatric patients stratified into two groups of 30 based on body mass index (BMI), using Chinese national screening criteria for childhood obesity (search). All participants received remifentanil at 2 µg/kg followed by remimazolam, with sedation depth assessed via the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale.
The study employed a modified up-and-down sequential allocation design, with an initial remimazolam dose of 0.2 mg/kg and adjacent increments or decrements of 0.02 mg/kg. An effective dose was defined as an MOAA/S score of less than 2 at one minute post-administration, with no body movement or only slight movement that did not interfere with the anesthesiologist's operation during nerve block.
Safety Observations
Adverse events were generally mild and transient across both groups. However, 12 patients experienced hypoxemia (SpO2 ≤ 92%), and notably, eight of these patients belonged to the obese cohort. While the difference between groups did not reach statistical significance, the finding suggests that obese pediatric patients may face a higher risk of respiratory obstruction during sedation.
The incidence of other adverse effects—including vomiting, hypotension, injection pain, and hiccups—was rare. Transient decreases in mean arterial pressure, heart rate, and SpO2 were observed following remimazolam administration across both groups.
Pharmacokinetic Rationale
The authors note that obesity (search) alters both pharmacokinetic and pharmacodynamic parameters. Increased central volume of distribution and altered drug clearance affect remimazolam plasma levels, while pharmacodynamic changes may influence the concentration producing 50% of the maximal effect (EC50). The findings align with prior research by Dong et al, who reported a 37.9%–38.6% decrease in the median effective concentration of propofol in morbidly obese patients.
For highly hydrophilic drugs or agents with exceptionally short elimination half-lives—such as remimazolam and remifentanil—dosing based on total body weight often results in higher plasma drug levels in obese children compared to healthy-weight peers. The study authors caution that competitive binding of free fatty acids in plasma can lead to rapid accumulation of these agents in active compartments, increasing the risk of profound sedation and cardiorespiratory suppression.
Clinical Implications and Limitations
The ED95 values, derived from probit analysis, were 0.20 mg/kg (95% CI, 0.18–0.23 mg/kg) for the obese group and 0.26 mg/kg (95% CI, 0.25–0.32 mg/kg) for the normal-weight group. However, the authors acknowledge that the modified sequential method provides an inadequate estimation for ED95, and no direct observations were made at this dose level.
Additional limitations include the fixed remifentanil dose of 2 µg/kg, as different institutions may use varying dosages that could influence the appropriate remimazolam dose. The study was also limited by regional and ethnic factors, having used Chinese national obesity (search) criteria.
The researchers conclude that directly determining weight-appropriate dosing for obese pediatric patients offers a more practical clinical approach than calculating lean body weight, which can be error-prone. Further studies are warranted to explore correlations between adjusted weight-based administration methods and lean body weight-based approaches in this vulnerable population.